TAS::75 0849::TAS SBIR TOPIC 304 PHASE I "DEVELOPMENT OF BLOOD-BASED METHODS FOR
TAS::75 0849::TAS SBIR 主题 304 第一阶段“基于血液的方法的开发
基本信息
- 批准号:8342473
- 负责人:
- 金额:$ 29.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-30 至 2012-06-29
- 项目状态:已结题
- 来源:
- 关键词:Adjuvant TherapyAmerican Cancer SocietyBiological AssayBiological MarkersBloodCancerousCessation of lifeClinicalDevelopmentDiagnosisDiagnostic Neoplasm StagingDiseaseERBB2 geneEarly DiagnosisEnzyme-Linked Immunosorbent AssayGoalsMethodsOperative Surgical ProceduresPatientsPhasePreventionRecurrenceRecurrent diseaseRiskSamplingScreening procedureSerumSmall Business Innovation Research GrantSpecificityTestingTissuesTumor stageUnited StatesValidationWomanbasecancer recurrencecost effectivefight againstimprovedmalignant breast neoplasmmolecular markertherapeutic target
项目摘要
According to the American Cancer Society, 192,370 women in the United States will be diagnosed with invasive breast cancer in 2010, leading to 40,170 deaths. Most women with breast cancer undergo surgery to remove the cancerous tissue and then receive additional treatment. Adjuvant therapy does not completely remove the risk of late cancer recurrence, even for women with low grade/low stage tumors. Thus, clinicians and patients still need to remain aware of this problem and this problem remains a high priority in our fight against breast cancer. In the past decades, identification and validation of ER, PR and HER2 as molecular markers and therapeutic targets for breast cancer has improved the patient survival. However, other breast cancer biomarkers currently identified lack either disease-related specificity or validated clinical values. Therefore, effective new breast cancer-specific molecular markers for prevention, early detection, and/or targeted treatment of the recurrent diseases are needed. Biomarkers present in blood, hold the best promise for disease screening. The goal of this project is to develop simple, quick and cost-effective homogeneous assays to evaluate whether AKR1B10 can be used as a breast cancer recurrence indicator by testing the serum samples from both cancer-recurrence positive and negative patients.
根据美国癌症学会的数据,2010年,192,370名妇女将被诊断出患有侵入性乳腺癌,导致40,170例死亡。大多数患有乳腺癌的妇女接受手术以去除癌组织,然后接受其他治疗。辅助治疗也不能完全消除晚期癌症复发的风险,即使对于患有低级/低阶段肿瘤的女性也是如此。因此,临床医生和患者仍然需要意识到这个问题,而这个问题仍然是我们与乳腺癌作斗争的重中之重。在过去的几十年中,ER,PR和HER2作为分子标记和乳腺癌治疗靶标的鉴定和验证提高了患者的生存率。但是,其他乳腺癌生物标志物目前发现缺乏与疾病相关的特异性或经过验证的临床值。因此,需要有效的新型乳腺癌特异性分子标记,用于预防,早期检测和/或需要对复发性疾病进行靶向治疗。血液中存在的生物标志物是疾病筛查的最佳前景。该项目的目的是开发简单,快速和具有成本效益的均质测定法,以评估AKR1B10是否可以通过测试来自癌症呈阳性和阴性患者的血清样本来将AKR1B10用作乳腺癌复发指标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LING TIAN其他文献
LING TIAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LING TIAN', 18)}}的其他基金
OTHER FUNCTIONS - PINCER-BASED IN-PROCESS ANALYZER FOR BIOLOGICS
其他功能 - 基于 PINCER 的生物制品在线分析仪
- 批准号:
8565184 - 财政年份:2012
- 资助金额:
$ 29.86万 - 项目类别:
Process Analytic Technologies (PAT) for Biologics
生物制剂过程分析技术 (PAT)
- 批准号:
8153982 - 财政年份:2010
- 资助金额:
$ 29.86万 - 项目类别:
TAS::75 0872::TAS APTAMER-BASED PINCERS FOR CARDIOVASCULAR BIOMARKERS
TAS::75 0872::TAS 基于适体的心血管生物标志物钳
- 批准号:
8175608 - 财政年份:2010
- 资助金额:
$ 29.86万 - 项目类别:
相似海外基金
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)
口腔鳞状细胞癌 (OC-SCC) 中的口腔定量组织形态风险分类器 (OHbIC)
- 批准号:
10322674 - 财政年份:2020
- 资助金额:
$ 29.86万 - 项目类别:
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)
口腔鳞状细胞癌 (OC-SCC) 中的口腔定量组织形态风险分类器 (OHbIC)
- 批准号:
10726124 - 财政年份:2020
- 资助金额:
$ 29.86万 - 项目类别:
Optimizing Thermal Ablation for Colon Cancer Liver Metastases: Rapid Tissue Analysis Allowing for Immediate Retreatment; Metabolic Imaging Biomarker Validation; and Predictive Genetic Signatures
优化结肠癌肝转移的热消融:快速组织分析可立即进行再治疗;
- 批准号:
10017172 - 财政年份:2019
- 资助金额:
$ 29.86万 - 项目类别:
Optimizing Thermal Ablation for Colon Cancer Liver Metastases: Rapid Tissue Analysis Allowing for Immediate Retreatment; Metabolic Imaging Biomarker Validation; and Predictive Genetic Signatures
优化结肠癌肝转移的热消融:快速组织分析可立即进行再治疗;
- 批准号:
10245245 - 财政年份:2019
- 资助金额:
$ 29.86万 - 项目类别:
Optimizing Thermal Ablation for Colon Cancer Liver Metastases: Rapid Tissue Analysis Allowing for Immediate Retreatment; Metabolic Imaging Biomarker Validation; and Predictive Genetic Signatures
优化结肠癌肝转移的热消融:快速组织分析可立即进行再治疗;
- 批准号:
9805609 - 财政年份:2019
- 资助金额:
$ 29.86万 - 项目类别: